LOGIN  |  REGISTER
Astria Therapeutics
Viking Therapeutics

Bionano Genomics to Report Fourth Quarter and Year End 2023 Financial Results and Host a Conference Call and Webcast on March 5, 2024

February 28, 2024 | Last Trade: US$4.00 0.13 -3.15

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 5, 2024, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2023 and to highlight recent corporate progress.

Conference Call & Webcast Details

Date:Tuesday, March 5th, 2024
Time:4:30 p.m. ET
Participant
Call Link:
Registration – Click Here
Webcast Link:https://edge.media-server.com/mmc/p/afaym86g/

Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano’s investor relations website at https://ir.bionano.com/ for at least 30 days.

CONTACTS

Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page